Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
Sponsor: Rhythm Pharmaceuticals, Inc.
Listed as NCT03746522, this PHASE3 trial focuses on Alström Syndrome (AS) and Bardet Biedl Syndrome (BBS) and remains completed. Sponsored by Rhythm Pharmaceuticals, Inc., it has been updated 23 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
23 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jan 2024 [monthly]
Completed PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 18 earlier versions
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE3
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rhythm Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .